Since the end of October 2022 and as of week 47, several EU/EEA countries have indicated an increase in paediatric hospitalisations due to RSV infections causing bronchiolitis, amidst concurrent circulation of other respiratory pathogens, such as the influenza and SARS-CoV-2 viruses.
In recent weeks, respiratory syncytial virus (RSV) circulation in the EU/EEA has intensified, with increasing transmission rates in all population groups and an earlier-than-usual start of the season. Several EU/EEA countries are experiencing high RSV circulation and the number of severe acute respiratory infections (SARI) due to RSV is increasing. At this time of the year RSV infections are not unusual, however this year there is more RSV activity and it began earlier than in pre-COVID-19 seasons.
A number of European countries (including Ireland, France, the Netherlands, Sweden and the United Kingdom) indicate an increase seen during 2022, particularly since September 2022, in the number of cases of invasive Group A Streptococcus (iGAS) disease among children less than ten years of age.
The EPIET/EUPHEM/PAE/MediPIET Outbreak Investigation module took place in Berlin, Germany from 5 – 9 December 2022. It was organised by the Robert Koch Institute in collaboration with ECDC.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 4 – 10 December 2022 and includes updates on COVID-19, Ebola virus, respiratory syncytial virus, streptococcal infection, diphtheria, seasonal influenza, mpox (monkeypox), hepatitis, MERS-CoV, meningitis, and mass gathering monitoring at the FIFA World Cup 2022 Qatar.
The European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC) convened on 6 and 7 December in Amsterdam the first meeting of the Immunisation and Vaccine Monitoring Advisory Board (IVMAB) of the Vaccine Monitoring Platform (VMP).